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Background. In hospitalized patients with coronavirus disease 2019 (COVID-19) pneumonia, progression to acute respiratory 
failure requiring invasive mechanical ventilation (MV) is associated with significant morbidity and mortality. Severe dysregulated 
systemic inflammation is the putative mechanism. We hypothesize that early prolonged methylprednisolone (MP) treatment could 
accelerate disease resolution, decreasing the need for intensive care unit (ICU) admission and mortality.
Methods. We conducted a multicenter observational study to explore the association between exposure to prolonged, low-dose 
MP treatment and need for ICU referral, intubation, or death within 28 days (composite primary end point) in patients with severe 
COVID-19 pneumonia admitted to Italian respiratory high-dependency units. Secondary outcomes were invasive MV-free days and 
changes in C-reactive protein (CRP) levels.
Results. Findings are reported as MP (n = 83) vs control (n = 90). The composite primary end point was met by 19 vs 40 (ad-
justed hazard ratio [aHR], 0.41; 95% CI, 0.24–0.72). Transfer to ICU and invasive MV were necessary in 15 vs 27 (P = .07) and 14 
vs 26 (P = .10), respectively. By day 28, the MP group had fewer deaths (6 vs 21; aHR, 0.29; 95% CI, 0.12–0.73) and more days off 
invasive MV (24.0 ± 9.0 vs 17.5 ± 12.8; P = .001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP 
levels. The complication rate was similar for the 2 groups (P = .84).
Conclusion. In patients with severe COVID-19 pneumonia, early administration of prolonged, low dose MP treatment was 
associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Treatment was safe and did not 
impact viral clearance. A large randomized controlled trial (RECOVERY trial) has been performed that validates these findings.
Clinical trial registration. ClinicalTrials.gov NCT04323592.
Keywords. ARDS; COVID-19; methylprednisolone; pneumonia; SARS-CoV-2.
Italy was the first European Country overwhelmed by the se-
vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
pandemic, experiencing an unsustainable burden on the health 
care system. The greatest impact was on intensive care units 
(ICUs) because 16% of hospitalized cases developed acute res-
piratory failure (ARF) requiring ICU admission [1]. COVID-19 
patients with ARF need weeks of mechanical ventilation (MV) 
and have an unacceptably high mortality rate [2]. This is an 
unprecedented global emergency where even countries with 
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advanced health care systems rapidly reach ICU saturation, and 
intensivists are forced to make difficult ethical decisions that 
are uncommon outside war zones. Any intervention directed at 
decreasing dependence on ventilators and mortality in COVID-
19 patients is an ethical imperative and would have a significant 
global impact on public health.
Over the last few decades, Italy has built-up a diffuse net-
work of respiratory high-dependency units (RHDUs), which 
also treat patients with severe pneumonia-related ARF re-
quiring continuous monitoring and noninvasive positive pres-
sure ventilation (NPPV) [3]. Patients with disease progression 
who require endotracheal intubation are transferred to the ICU. 
During the pandemic, RHDUs were pivotal in reducing ICU re-
ferral [4].
Indeed, patients with severe COVID-19 have exhausted 
antiviral defenses and massive tissue and systemic inflamma-
tory response. Corticosteroids are powerful anti-inflammatory 
drugs that could have a role in promoting the resolution of ARF 
in patients with severe COVID-19 infection [5]. The rationale 
for prolonged, low-dose corticosteroid treatment in severe 
COVID-19 was recently reviewed [6].
We hypothesized that early MP treatment in hypoxemic pa-
tients with severe SARS-CoV-2 pneumonia who are at higher 
risk for ARF progression requiring invasive MV may quicken 
disease resolution, reducing the need for ICU support and mor-
tality. We investigated the association between early interven-
tion with prolonged MP treatment in this high-risk group and 
the risk for ICU admission, the need for invasive MV, and all-
cause death by day 28.
METHODS
Study Design, Setting, and Participants
We conducted a multicenter, observational, longitudinal study 
to evaluate the association between MP treatment and out-
come in consecutive patients with severe COVID-19 pneu-
monia admitted to 14 Italian RHDUs between February 27 and 
April 24, 2020. Follow-up continued through May 21, 2020. 
The composite primary endpoint included admission to ICU, 
need for invasive MV, or all-cause death by day 28, while sec-
ondary endpoints were MV (combined invasive and nonin-
vasive or invasive alone)-free days by day 28 [7] and changes 
in C-reactive protein (CRP) levels. The study was carried out 
in accordance with the Declaration of Helsinki. It was regis-
tered on ClinicalTrials.gov (NCT043235929) after approval 
by the referral Ethics Committee for the Coordinating Centre 
(University Hospital of Trieste, #CEUR-2020-Os-052).
The study baseline was defined as the time of fulfillment 
of inclusion criteria after admission to RHDU. Inclusion 
criteria were the following: (1) SARS-CoV-2 positive (on 
swab or bronchial wash); (2) age >18  years and <80  years; 
(3) PaO2:FiO2  <250  mmHg; (4) bilateral infiltrates; (5) 
CRP >100  mg/L; and/or 6)  diagnosis of acute respiratory 
distress syndrome (ARDS) according to the Berlin definition [8] 
as an alternative to criteria (4) and (5). Exclusion criteria were 
heart failure as the main cause of ARF, decompensated liver 
cirrhosis, immunosuppression (ie, cancer on treatment, post–
organ transplantation, HIV-positive, on immunosuppressant 
therapy), dialysis dependence, on long-term oxygen or home 
mechanical ventilation, idiopathic pulmonary fibrosis, neuro-
muscular disorders, dementia or a decompensated psychiatric 
disorder, severe neurodegenerative conditions, on chronic ste-
roid therapy, pregnancy, a do-not-resuscitate order, and use of 
tocilizumab or other experimental treatment. Patients in both 
study groups received standard of care, comprising noninva-
sive respiratory support, antibiotics, antivirals, vasopressors, 
and renal replacement therapy as deemed suitable by the health 
care team.
Exposure to methylprednisolone (nonpatented drug, ATC 
code H02AB04) complied with the following protocol: a 
loading dose of 80 mg intravenously (iv) at study entry (base-
line), followed by an infusion of 80 mg/d in 240 mL of normal 
saline at 10  mL/h for at least 8  days, until achieving either a 
PaO2:FiO2 >350 mmHg or a CRP <20 mg/L; after which, oral 
administration at 16  mg or 20  mg iv twice daily until CRP 
reached <20% of the normal range or a PaO2:FiO2 >400 (al-
ternative SatHbO2 ≥95% on room air). The MP protocol was 
developed by the coordinating center in accordance with the 
“Recommendation for COVID-19 Clinical Management” by the 
National Institute for the Infectious Diseases “L. Spallanzani,” 
Rome, Italy [9]. The decision to apply the protocol to COVID-
19 was left to the discretion of the treating team for each in-
dividual patient. Unexposed patients (controls) were selected 
from concurrent consecutive COVID-19 patients with the same 
inclusion and exclusion criteria.
Data Sources and Variables
Demographic details and laboratory, clinical, and outcome vari-
ables were manually extracted from electronic medical records 
or charts and anonymously coded into a standardized data col-
lection form. Three independent physicians checked the data, 
and 2 researchers adjudicated any difference in interpretation 
between the primary reviewers.
Serial measurements included arterial blood gas, CRP, 
D-dimer, white cell count with differential, hemoglobin, vari-
ables for the calculation of the Sequential Organ Failure 
Assessment (SOFA) score [10], and days free from invasive or 
noninvasive MV until study day 28. Laboratory methodologies, 
including SARS-CoV-2 detection by reverse transcription pol-
ymerase chain reaction (RT-PCR), and reference values were 
comparable between centers. Other collected data included date 
of death, admission to the ICU, dates of discharge from hospital 
and ICU, intrahospital medications, in-hospital adverse events, 
and comorbidities. Samples from seriated nasopharyngeal 
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Statistical Methods
Considering a study power (1-beta) of 80% and a probability 
of type 1 error (alpha) of 0.05, assuming that the proportion of 
treated patients with the primary end point was 0.7 under the 
null hypothesis (according to available information from Fang 
et al. [11]) and 0.42 under the alternative hypothesis, and con-
sidering a 5% dropout rate, a minimum study sample of 104 
patients was established. Data were described using absolute 
and relative frequencies (percentage) or position indices (mean 
or median) and relative dispersion indices (SD or interquartile 
range), as appropriate according to the type and distribution 
of the variable analyzed. The differences between study groups 
(MP-treated and control) in the proportion of patients reaching 
the primary end point were evaluated using a 2-sided chi-square 
test. The difference in numerical variables between groups was 
calculated using the Student t test or Wilcoxon rank-sum test, 
depending on the distribution of the variables.
Differences between study groups concerning categorical 
and dichotomous variables were evaluated by means of the chi-
square test or Fisher exact test, as appropriate. Time-to-event 
analyses were performed for both the composite primary end 
point and death alone. Time at risk for all-cause death was com-
puted from the date of study enrollment up to the date of death, 
hospital discharge, or 28 days, whichever came first. Event-free 
probabilities were estimated by the Kaplan-Meier method, and 
differences between groups were assessed by the log-rank test. 
Multivariable Cox proportional hazard models estimated the 
hazard ratio (HR) of both the primary composite end point and 
all-cause death, with corresponding 95% confidence intervals, 
taking into account the confounding factors (ie, sex, age, and 
baseline values of SOFA score, PaO2:FiO2, CRP levels) poten-
tially associated with the outcome. These variables and others 
with baseline differences (eg, smoke) were tested in univariate 
survival models, and variables significant at P = .1 were tested 
in the multivariable models. Proportional hazards assumption 
was assessed by visual inspection of the log(-log(survival)) plot. 
There were no missing data with regard either to the composite 
primary end point and the adjustment factors included in the 
final Cox models or to MV-free days. Available case analysis 
was performed for time variation of C-reactive protein (CRP) 
and PaO2:FiO2 levels. All tests were 2-sided, and a P value of 
<.05 was considered statistically significant.
Sensitivity analyses were completed as recommended by 
the STROBE guidelines for reporting observational studies 
[12]. Although a protocol was used to standardize study 
measures, we conducted a sensitivity analysis to account for 
potential variance in medical decision-making that could po-
tentially impact the primary composite outcome. We exam-
ined hypothetical scenarios against the hypothesis by varying 
the number of subjects meeting the primary composite out-
come by 3 and 5 subjects to account for potential bias in both 
groups.
RESULTS
Between February 27 and April 24, 2020, 322 consecutive 
SARS-CoV-2-positive patients who were admitted to 1 of 14 
RHDUs with severe pneumonia were assessed for study eligi-
bility. A  total of 173 patients (83 MP-treated exposed and 90 
untreated controls) were enrolled, while 149 were excluded, as 
detailed in Figure 1.
322 patients assessed for eligibility
173 included in the analysis
83 exposed to
methylprednisolone
90 not exposed to
methylprednisolone
107 failed inclusion (n = 72) or met exclusion criteria (n = 35)
4 protocol deviation
10 intubated before study baseline
28 reached primary end point within 24h (dropouts)  
Figure 1. Flowchart of the study population. Failed to meet inclusion criteria (n = 72): age >80 years (n = 9), criteria for PaO2:FiO2, C-reactive protein level, or acute res-
piratory distress syndrome (n = 63). Met exclusion criteria (n = 35): heart failure as main cause of acute respiratory failure (n = 2), decompensated liver cirrhosis (n = 3), on 
long-term oxygen therapy and/or home ventilation (n = 2), dementia or severe neurodegenerative condition (n = 14), active cancer (n = 3), on chronic steroid therapy (n = 4), 
use of tocilizumab or other experimental treatment (n = 7). Twenty-eight patients who reached the primary end point before admission to a respiratory high-dependency unit 
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The findings are reported as MP group vs control group. 
RHDU admission days to study enrollment were comparable 
(0.83 ± 2.02 vs 0.56 ± 1.50; P = .32). Table 1 shows how the pa-
tients’ baseline characteristics did not differ between groups. The 
mean duration of iv MP treatment was 9.11 ± 2.4 days, while 
the total duration of MP treatment was 13.7 ± 3.6 days. Table 2 
reports the main study outcomes. The composite primary end 
point was reached by 19 vs 40 (22.9% vs 44.4%; P = .003; ad-
justed hazard ratio [HR], 0.41; 95% CI, 0.24–0.72), indicating 
a reduction of 59% in the risk of ICU referral, invasive MV, or 
death within 28 days. In particular, ICU transfer was necessary 
in 15 vs 27 (18.1% vs 30.0%; P = .07) and invasive MV in 14 vs 
26 (16.9% vs 28.9%; P = .10).
MP-treated patients had a 28-day lower risk of all-cause 
death than untreated ones (6 deaths, 7.2%, vs 21 deaths, 
23.3%; P = .005), with a corresponding adjusted HR equal to 
0.29 (95% CI, 0.12–0.73), indicating a 71% reduction in risk 
of death in MP patients compared with controls. Kaplan-
Meier survival curves (Figure  2) showed a statistically sig-
nificant difference between groups (log-rank test P = .003), 
with survival probabilities at 28  days of 91.6% (95% CI, 
82.2%–96.2%) for MP treated and 68.2% (95% CI, 53.8%–
78.9%) for control patients. The HRs did not substantially 
change when other variables were included in the adjusted 
Cox models (eg, other allowed treatments, body mass index, 
smoking, NPPV, and high-flow nasal cannula) (data not 
shown). The Kaplan-Meier curves shown in Supplementary 
Figure 1 illustrate timing to removal of mechanical ventila-
tion in both groups.
For the secondary end points (Table 2), we observed a sig-
nificant increment in both MV-free days by day 28 outcomes, 
combined invasive MV and NPPV (19.1 ± 8.7 vs 14.3 ± 11.7; 
P = .003), and invasive-MV-free days alone (24 ± 9 vs 
17.5 ± 12.8; P = .001). MP exposure was associated with a sig-
nificant intrapatient median variation in PaO2:FiO2 at day 3 
compared with baseline (54.0 [7.0 to 155.0] vs 6.9 [–41.5 to 
77.0]; P < .001) but not at days 7, 14, and 28 (Figure 3). Median 
variation in CRP levels was also prominent in the MP group 
at day 3 (–85.0 [–133.0 to –42.5] vs –22.0 [–65.0 to 21.3]; 
P < .001) and at day 7 (–99.4 [–162.0 to –62.3] vs –66.1 [–116.0 
to –0.7]; P < .001) compared with baseline, but not at days 14 
and 28 (Figure 3). No differences were noted between groups 
in intrapatient median lymphocyte variation at days 3, 7, and 
14 compared with baseline, as detailed in Table  2 and shown 
in Figure 3. Hospital length of stay did not differ between the 
groups (P = .38). No tracheostomy was necessary in MP pa-
tients vs 12 controls (odds ratio [OR], 0.04; 95% CI, 0.002–0.64; 
P < .001). Concerning intrahospital adverse events of any type 
(Supplementary Table 1), only the occurrence of hyperglycemia 
in nondiabetic patients, or severe glycemic decompensation in 
diabetic patients, and agitation was significantly higher in the 
MP group compared with control (8 vs 0; P = .002; and 9 vs 2; 
P = .03; respectively). No adverse event led to MP discontinu-
ation. Concomitant in-hospital treatments are summarized in 
Supplementary Table 2.
There were no relevant differences in viral genome sequencing 
in the 2 first recruited patients compared with the average 
sequences reported in open source repositories (Supplementary 
Figure 2). Nor was any observed in viral shedding, determined 
as time lapse (days) between hospital admission and the first 
negative RT-PCR for SARS-CoV-2 nasopharyngeal swabs, in a 





(n = 90) P Valuea
Age, mean (SD) 64.4 (10.7) 67.1 (8.2) .07
Male sex, No. (%) 54 (65.1) 66 (73.3) .25
BMI ≥30 kg/m2, No. 
(%)b
19 (33.3) 18 (32.7) 1.00
Ever smoker, No. (%)c 22 (29.7) 29 (45.3) .05
Presence of major 
comorbidities, No. 
(%)
63 (75.9) 74 (82.2) .35
 Hypertension, No. 
(%)
36 (43.4) 51 (56.7) .09
 Diabetes, No. (%) 19 (22.9) 25 (27.8) .49
 Asthma/COPD, No. 
(%)
7 (8.4) 9 (10.0) .80
 OSAS/OHS, No. (%) 5 (6.0) 7 (7.8) .77
 Congestive heart 
failure, No. (%)




2 (2.4) 9 (10.0) .06
 Chronic kidney dis-
ease, No. (%)
5 (6.0) 4 (4.4) .74
 History of malig-
nancy, No. (%)
7 (8.4) 4 (4.4) .36
PaO2:FiO2, mean (SD), 
mmHg
152.0 (49.8) 151.0 (60.3) .90
Respiratory rate, mean 
(SD),d breaths/min
23.7 (5.9) 25.3 (6.8) .16
CRP, mg/L, mean (SD) 136.9 (72.6) 148.6 (75.6) .30
D-dimer, median (IQR), 
μg/FEU/L
780 (540–1214) 871 (472–1517) .82
LDH, mean (SD), U/L 370.5 (130.9) 395.3 (169.3) .34
Lymphocyte count, 
mean (SD)
916.2 (657.0) 954.5 (914.7) .76
SOFA score, median 
(IQR)
3 (2–4) 3 (2–4) .96
Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, 
C-reactive protein; IQR interquartile range; LDH, lactate dehydrogenase; PaO2:FiO2, ratio 
of partial pressure of arterial oxygen (PaO2 in mmHg) to fractional inspired oxygen (FiO2); 
OSAS/OHS, obstructive sleep apnea syndrome/obesity-hypoventilation syndrome; SOFA, 
Sequential Organ Failure Assessment. 
aP value of the Fisher exact test for dichotomous variables, unpaired Student t test or 
Wilcoxon; rank-sum test for numerical variables, as appropriate.
bMissing data: 35 (38.9) methylprednisolone, 26 (31.3) control group.
cMissing data: 26 (28.9) methylprednisolone, 9 (10.8) control group. 
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sample of 41 MP-treated patients compared with 28 untreated 
ones (19.05 ± 6.11 vs 20.68 ± 7.05; P = .31).
Sensitivity analyses (Supplementary Table 3) show that the 
primary composite outcome still significantly differs between 
the MP and control groups in scenarios biased against the orig-
inal hypothesis.
DISCUSSION
In our multicenter study, patients exposed to MP encountered 
the primary composite end point of ICU referral, need for in-
vasive MV, or in-hospital all-cause death significantly less com-
pared with the control group (adjusted HR, 0.41). By day 28, 
MP treatment was associated with a significant reduction in 
Table 2. Distribution of 173 Study Patients According to Study Group and Clinical Outcomes at 28 Days
Methylprednisolone  
(n = 83) Control (n = 90) P Valuea
Crude HRb  
(95% CI)
Adj. HR  
(95% CI)c P Valuec
Major outcomes       
 Composite primary end point, No. (%) 19 (22.9) 40 (44.4) .003 0.43 (0.25–0.74) 0.41 (0.24–0.72) .002
  Transfer to intensive care unit, No. (%) 15 (18.1) 27 (30.0) .067 ·· ·· ··
  Invasive mechanical ventilation, No. (%) 14 (16.9) 26 (28.9) .095 ·· ·· ··
  Death, No. (%) 6 (7.2) 21 (23.3) .005 0.28 (0.11–0.68) 0.29 (0.12–0.73) .009
Other outcomes       
 Mechanical ventilation-free days, mean (SD)d 19.1 (8.7) 14.3 (11.7) .003    
 Invasive mechanical ventilation-free days, mean (SD) 24.0 (9.0) 17.5 (12.8) .001    
 Invasive mechanical ventilation, median (IQR),e d 7 (5.5 to 15.5) 14.5 (12 to 22) .031    
 Required tracheotomy, No. (%) 0 (0.0) 12 (13.3) <.001    
 Intrapatient difference between:       
  CRP at day 3 vs baseline, median (IQR) –85.0 (–133.0 to –42.5) –22.0 (–65.0 to 21.3) <.001    
  CRP at day 7 vs baseline, median (IQR) –99.4 (–162 to –62.3) –66.1 (–116 to –0.7) <.001    
  PaO2:FiO2 at day 3 vs baseline, median (IQR) 54.0 (7.0 to 155.0) 6.9 (–41.5 to 77.0) <.001    
  PaO2:FiO2 at day 7 vs baseline, median (IQR) 97.5 (42.0 to 162.0) 68.0 (–5.5 to 139.0) .09    
  Lymphocytes at day 3 vs baseline, median (IQR) –45 (–285 to 150) 0 (–110 to 170) .18    
  Lymphocytes at day 7 vs baseline, median (IQR) 110 (–170 to 480) 130 (–140 to 350) .88    
  Lymphocytes at day 14 vs baseline, median (IQR) 590 (–70 to 1390) 600 (230 to 800) .68    
Abbreviations: CRP, C-reactive protein; HR, hazard ratio; IQR, interquartile range; PaO2:FiO2, ratio of partial pressure of arterial oxygen (PaO2 in mmHg) to fractional inspired oxygen (FiO2); 
SOFA, Sequential Organ Failure Assessment score.
aP value of chi-square or Fisher exact test for dichotomous variables; unpaired T-test or Wilcoxon rank-sum test for numerical variables, as appropriate.
bHR of event among methyprednisolone group vs control group, estimated using Cox regression model. The crude odds ratio (95% CI) for the composite outcomes is 0.37 (0.19–0.71).
cCox regression model was adjusted for sex, age, baseline SOFA score, baseline PaO2:FiO2, and baseline CRP.
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mortality (adjusted HR, 0.29) and an increase in MV-free days. 
Among patients transferred to the ICU, MP-treated patients had 
a 7.5-day median reduction (P = .03) in the duration of invasive 
MV. In line with these data, fewer MP-treated patients required 
tracheotomy than controls (0 vs 12; P < .001). MP-treated pa-
tients had a higher reduction in CRP levels than controls. This 
was statistically significant on days 3 and 7 from baseline, and 
there was a quicker improvement in PaO2:FiO2 ratio on day 3 for 
MP-treated patients. There was no overall increase in adverse 
events between groups, except for an increase in hyperglycemia 
and mild agitation in the MP-treated patients; no adverse event 
necessitated MP discontinuation. No difference was observed 
in viral shedding, determined as the number of days between 
hospital referral and the first negative nasopharyngeal swab.
Early interventions aimed at downregulating the SARS-
CoV-2-associated hyperimmune response in severe COVID-19 
patients may well avoid disease progression and enhance pneu-
monia resolution. The cytokine profile reported for these pa-
tients [13] is within the broad range of regulation provided by 
corticosteroids [14], particularly MP, which is associated with 
optimal lung penetration [15]. Our study protocol involved an 
initial iv bolus to achieve rapid, almost complete glucocorticoid 
receptor saturation, followed by an infusion to reach a total 160-
mg dose over the first 24 hours and to maintain high levels of re-
sponse throughout the treatment period. After day 7, treatment 
duration was guided by monitoring the anti-inflammatory re-
sponse and oxygenation parameters. Our study investigated a 
dose that was greater than double the one investigated in the 
RECOVERY RCT and included tapering to minimize the risk 
of rebound inflammation.
This might explain the rapid reduction observed in inflam-
matory markers. Treatment duration was guided by monitoring 
the anti-inflammatory response and oxygenation after at least 
8  days. Our MP treatment response is similar to that of ran-
domized controlled studies (RCTs) in COVID-19 [16], nonviral 
ARDS [17], and severe pneumonia [18], as well as to that of 
large-scale observational studies in severe pneumonia caused by 
SARS-CoV (n = 7008) [19–21] and H1N1 influenza (n = 2141) 
[22]. Additional support for the use of methylprednisolone 
in COVID-19 originates from transcriptomics data. After 
matching the expression changes induced by SARS-CoV2 
in human lung tissue tissues and A549 lung cell line against 
the expression changes triggered by 5694 Food and Drug 
Administration–approved drugs, methylprednisolone was 
found to be the drug with the greatest potential to revert the 
changes induced by COVID-19 [23].
This study was carried out before the results of the RECOVERY 
RCT became available, as visible in ClinicalTrials.gov posting 
records (results first posted June 4, 2020). In the RECOVERY 
trial, patients were randomized to receive dexamethasone at a 
dose of 6 mg/d or standard of care alone, providing evidence of 
lower 28-day mortality in the dexamethasone group compared 
with the usual care group only among those who were receiving 
either invasive mechanical ventilation (29.3% vs 41.4%) or ox-
ygen alone (23.3% vs 26.2%) at randomization, but not among 
those receiving no respiratory support. In our study, both mor-
tality and mortality reduction in the MP group were better 
than reported in the RECOVERY trial. Apart from the different 
study design and setting, we speculate that this difference is 
possibly due to several factors: First, the RECOVERY trial uses 
a different drug (dexamethasone) at a lower dose, equivalent 
to ~32 mg of methylprednisolone [24]. Second, it is likely that 
MP has pharmacokinetic and pharmacodynamic advantages 








































































































Figure 3. Time course of C-reactive protein and PaO2:FiO2 variation. Upper 
panel: time course of C-reactive protein levels (mean ± SE). The differences be-
tween groups were significant at days 3 and 7. Middle panel: time course of mean 
PaO2:FiO2. The differences between groups were significant at day 3. Lower panel: 
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comparison [23]. Third, in the RECOVERY trial, the impact of 
the study treatment on survival seems to correlate with the need 
for respiratory support and therefore with illness severity. With 
this regard, it has been noticed that glucocorticoids are not ef-
fective in patients without ARDS and/or sepsis [18]. While per-
missive inclusion criteria are needed to recruit large populations 
in RCTs, we designed strict criteria that allowed us to include in 
the analyses only patients affected by severe pneumonia/ARDS 
with high levels of systemic inflammation and need for respi-
ratory support. It is worth stressing that inflammatory organ 
injury with subsequent dysregulated host response is thought 
to be the main mechanism of damage in COVID-19; as a conse-
quence, the subgroup of patients with markedly elevated levels 
of inflammatory markers is the one supposed to benefit most 
from therapeutic interventions aimed at reducing inflammatory 
organ injury, including corticosteroids.
The safety profile reported in our study is consistent with 
the findings of multiple RCTs investigating prolonged cortico-
steroid treatment in thousands of patients with severe sepsis, 
septic shock, and ARDS [17]. In these RCTs, hyperglycemia was 
transient in response to the initial loading bolus and did not 
negatively impact outcome [17]. Viral shedding in both groups 
of our study was in agreement with the international literature 
[25, 26]. The World Health Organization quotes a Middle East 
respiratory syndrome coronavirus study to warn about the risk 
of reduction in viral clearance with corticosteroid treatment. In 
the Arabi et al. study [27], however, those who received cortico-
steroid treatment for >7 days (similar to our study) had a 50% 
reduction in mortality (adjusted OR, 0.51; 95% CI, 0.26–1.00; 
P = .05) and no impact on viral clearance (aHR, 0.94; 95% CI, 
0.36–2.47; P = .90). Moreover, there is no evidence linking 
delayed viral clearance to worsened outcome in critically ill 
COVID-19 patients, and it is unlikely that it would have a 
greater negative impact than the host’s own cytokine storm [28].
The observational design of our study implies some obvious 
limitations, namely possible restricted control over data collec-
tion and potential inclusion biases. However, internal validity 
was achieved by (1) the comparability of concurrent groups 
at baseline, (2) accounting for potential confounders into the 
multivariable Cox regression analyses, and (3) conducting sen-
sitivity analysis to assess for potential bias in outcome ascer-
tainment potentially influenced by medical decision-making. 
Our study’s strengths include a prospective evaluation of a 
predesigned intervention protocol based on established phar-
macological principles in patients at high risk of progression to 
ARF and death. The limitations of the study are that we did not 
control for center effects and site investigators were not blinded 
to treatment, as with any observational study. Despite these lim-
itations, we believe that our findings represent valid and gener-
alizable conclusions, which have been further strengthened by 
the recently published RECOVERY RCT.
Indeed, we observed benefits when MP treatment was started 
early and prolonged in the hospitalization of hypoxemic patients 
with COVID-19 pneumonia at high risk of ARF progression. 
MP treatment was demonstrated to be safe and also allowed for 
a significant reduction in mortality and immediate improve-
ments in systemic inflammation and oxygenation markers, as 
well as reducing invasive MV times. We believe our data sup-
port the evidence that early low-dose prolonged MP treatment 
can decrease ICU burden and mortality, thereby contributing to 
reducing the concern surrounding this therapeutic approach in 
patients admitted with ARF due to severe SARS-CoV-2 pneu-
monia in the current state of affairs.
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